Krystal Biotech reported continued progress with its first commercial product, VYJUVEK, demonstrating expanding market launches and solidifying manufacturing capabilities. The company’s proprietary HSV-1 gene therapy platform underpins a pipeline targeting rare genetic diseases beyond dystrophic epidermolysis bullosa (DEB). The latest quarterly filing highlights sustained R&D focus and expanding specialty distribution, while financials show a strong liquidity position supporting clinical advancement.